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Evaluation of new drug combinations is needed to improve patients’ prognosis in advanced hepatocellular carcinoma (HCC). The
purpose of this study was to evaluate the safety and efficacy of the capecitabine–oxaliplatine combination (XELOX) in HCC patients.
First-line chemotherapy with XELOX regimen consisting of a 3-week cycle of intravenous oxaliplatin (130mgm
 2) on Day 1, and
oral capecitabine twice daily from Days 1–14 (1000mgm
 2) was administered in patients with measurable, unresectable HCC. Fifty
patients (male, 88%; median age, 68 years) received a total of 295 cycles (median, 6) of treatment. Disease control (three partial
responses, 29 stable diseases) rate was 72% (95% CI 57–83%). Median overall and median progression-free (PFS) survival was 9.3
months and 4.1 months, respectively. Progression-free survival rates at 6 and 12 months were 38% (95% CI 26–52%) and 14% (95%
CI 7–26%), respectively. Main grade 3–4 drug-related toxicities included diarrhoea (16%), elevation of aminotransferases and/or
bilirubin (16%), thrombocytopenia (12%), and neurotoxicity (6%). Capecitabine plus oxaliplatin regimen showed modest anti-tumour
activity with tolerable toxicities in patients with advanced HCC. However, the manageable toxicity profile and the encouraging
disease control rate deserve further attention for this convenient, outpatient-based chemotherapy regimen.
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Worldwide, hepatocellular carcinoma (HCC) is the fifth most
common cancer and the third most common cause of cancer-
related death (Parkin et al, 2001). It is seen primarily in the setting
of chronic liver disease or cirrhosis. As a result of the tumour
extent and/or underlying decompensated cirrhosis at time of
diagnosis, only a few patients are eligible for radical treatments
with curative intent (ie, surgical resection, liver transplantation,
percutaneous ablation). Chemoembolisation, which has been
shown to improve survival in selected patients (Bruix et al,
2004), is not feasible in case of portal vein thrombosis or illogical
in case of extrahepatic spread. Therefore, a substantial proportion
of patients with advanced HCC are eligible for palliative systemic
therapy. However, no chemotherapeutic agent including doxo-
rubicin alone or in combination has produced a substantial
improvement in patient survival rates as a result of poor response
rate and increased toxicity (Lai et al, 1988; Burroughs et al, 2004;
Yeo et al, 2005).
Unlike other platinum salts, oxaliplatin has consistently shown
preclinical and clinical anti-tumour activity against gastrointest-
inal cancers without nephrotoxicity. In colon cancer it is well
known that the combination of 5-fluorouracil (5-FU), either as a
short or continuous infusion combined with oxaliplatin gives
improved overall response rate compared to 5-FU alone (de
Gramont et al, 2000). Sensitive peripheral neuropathy is the most
frequent limiting toxicity with oxaliplatin, but this is reversible
with treatment discontinuation (Brienza et al, 1995). A pilot study
conducted by Bearz et al (2001) and updated by Frustaci et al
(2003) in 31 patients suffering from inoperable or metastatic HCC
showed the feasibility and demonstrated some efficacy of 5-FU/
oxaliplatin (FOLFOX) combination with an overall response rate
of 29%.
Capecitabine is a rationally designed, orally administered,
tumour-selective fluoropyrimidine that mimics continuous infu-
sion of 5-FU. Capecitabine is converted to 5-FU preferentially in
tumour tissue by the enzyme thymidine phosphorylase (Miwa
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set al, 1998; Schuller et al, 2000) and has been approved by the Food
and Drug Administration and the European Agency for the
Evaluation of Medicinal Products (EMEA) to treat patients with
colorectal cancer (CRC). The efficacy and toxicity of capecitabine
in 37 patients with unresected HCC was analysed in one
retrospective study reported by Patt et al (2004); capecitabine
was found to be safe in patients with cirrhosis and provided an
11% response rate including one radiologically confirmed
complete response (Cassidy et al, 2004).
The rationale for developing the capecitabine–oxaliplatin
combination in HCC was based on (1) the synergy of these two
drugs (Cassidy et al, 2004); (2) the lack of renal toxicity of
oxaliplatin in cirrhotic patients (low risk of oedema and ascites
due to non-required hyperhydration) (Brienza et al, 1995); (3) the
clinical activity and favourable toxicity profile of capecitabine
alone and in combination with oxaliplatin in advanced or
metastatic CRC (Van Cutsem et al, 2001; Borner et al, 2002;
Cassidy et al, 2004); and (4) no dose adjustment required for
capecitabine and oxaliplatin in hepatic dysfunction (Brienza et al,
1995; Twelves et al, 1999). This French, multicentre, open-label,
phase II study aimed to assess efficacy and safety of first-line
capecitabine plus oxaliplatin (XELOX) regimen in patients with
unresectable HCC without decompensated cirrhosis.
PATIENTS AND METHODS
Patients
Patients who were not suitable for surgical resection, liver
transplantation, or local ablation techniques, with either histolo-
gically proven HCC, or combination of liver cirrhosis, radiologi-
cally documented hypervascular liver tumour and alphafetoprotein
(AFP) level4400ngml
 1, were eligible to this open-label, phase II
study. Other eligibility criteria were measurable tumour mass
X2cm in diameter; Cancer of the Liver Italian Program score
(CLIP) (cancer of the liver program investigators, 1998) o4;
age418 years; World Health Organization (WHO) performance
status (PS) 0–2; Child–Pugh score of A or B; life expectancy 412
weeks; adequate hepatic, renal and bone marrow function (serum
bilirubin p1.5 the upper limit of normal (ULN), creatinine p1.5
ULN, neutrophils41.5gl
 1, platelets475gl
 1). Main exclusion
criteria were Child–Pugh score of C, previous systemic che-
motherapy, chemoembolisation or embolisation, or radiotherapy;
concomitant anti-tumour therapy including tamoxifen, interferon
and somatostatin analogues, central nervous system metastases,
severe cardiac and/or respiratory failure, concurrent malignancy,
and baseline sensitive peripheral neuropathy; and pregnant or
lactating females. Patients provided written informed consent.
Study design
This was a multicentre, open-label phase II study conducted at six
centres in France. The study protocol was approved by an
independent Ethics Committee (Comite ´ Consultatif de Protection
des Personnes dans la Recherche Biome ´dicale, C.C.P.P.R.B. at
Bice ˆtre Hospital, Paris, France) and carried out according to
International Conference on Harmonisation/WHO Good Clinical
Practice standards Guidelines and declaration of Helsinki.
Treatment protocol
Capecitabine plus oxaliplatin regimen was administered as a 3-
week cycle. In each cycle, oxaliplatin was administered at a total
dose of 130mgm
 2 as a 2-h i.v. infusion on Day 1, and
capecitabine 1000mgm
 2 was taken orally twice daily (total daily
dose 2000mgm
 2) on Days 1–14.
Complete blood cell and platelet counts were performed weekly,
and physical examination, biology (serum AFP, transaminases,
alkaline phosphatases, bilirubin, lactate dehydrogenase, g-glutamyl
transferase, albumin, prothrombin time (PT), and creatinine), and
safety assessments were performed before each cycle of chemo-
therapy. Analysis of AFP level and tumour assessment (computed
tomography (CT) scan or magnetic resonance imaging) were
undertaken every three cycles. Objective response (OR) was
confirmed by a second evaluation 4 weeks later. Objective and
discordant responses were reviewed by an independent radiologist.
Study treatment was continued until either disease progression
according to Response Evaluation Criteria in Solid Tumours
(RECIST) (Therasse et al, 2000); unacceptable toxicity; or patient’s
refusal. After cessation of study treatment, second-line therapy of
HCC was at the investigator’s discretion.
Toxicity assessment and dose modification
Safety was assessed according to the National Cancer Institute –
Common Terminology Criteria for Adverse Events version 2.0, but
any fatal or non-fatal decompensation of cirrhosis was considered
separately. The oxaliplatin-specific scale was used to assess
oxaliplatin neurotoxicity (Caussanel et al, 1990). In cases of non-
neurological grade 3–4 toxicity, oxaliplatin and capecitabine were
reintroduced at the following cycle only after recovery to grade
0–1 toxicity with a 20% dose reduction after the first occurrence, a
40% dose reduction after the second episode and treatment
cessation after the third episode.
In cases of grade 2 sensory neuropathy (defined as dysaesthesia/
paraesthesia persisting over two cycles, without dysfunction), a
20% dose reduction was applied to oxaliplatin in the subsequent
cycle, whereas in case of grade 3 neuropathy (defined as
permanent functioning discomfort) oxaliplatin was stopped and
capecitabine was administered alone.
Statistical analysis
The main objective of the study was to assess OR rate according to
RECIST classification of the XELOX combination. Secondary
objectives were to assess response and/or stabilisation durations,
progression-free survival (PFS), overall survival (OS), and safety
profile of the combination. A one-step Fleming design with a 5%
type I error (one-sided) 95% power, a 10% OR rate as null
hypothesis, and a 30% as alternative hypothesis was used (Fleming,
1982; Machin et al, 1997). The planned accrual was for 40 patients.
Because of frequent early progression or decompensated liver
disease in patients with HCC and cirrhosis, the number of patients
included was increased to 50 patients. Disease progression was
defined as the time from the start of therapy until tumour
progression or death whatever its cause, and OS from the start of
therapy to the date of the death or last follow-up. Time-to-event
parameters were analysed using Kaplan–Meier product limit
estimates, and between–group comparisons were performed using
the Log-rank test. Cox regression model was used for multi-
dimensional analysis. All reported P-value were two-sided.
RESULTS
Patient characteristics
Fifty patients (44 men, 6 women), median age 68 years (range: 24–
82 years), were included in the trial between December 2003 and
September 2004. Patients’ baseline characteristics are shown in
Table 1. Thirty-three patients (66%) had a history of alcohol abuse
either alone (28 patients) or combined with either haemochroma-
tosis (two patients), hepatitis B virus (HBV) (two patients) or
hepatitis C virus (HCV) (one patient). Aetiology was viral in eight
other patients (16%): HCV for five patients and HBV for three
patients. Cirrhosis was present in 36 patients (72%) and 9 patients
(18%) had normal serum AFP at baseline (missing in one patient).
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A total of 295 cycles of chemotherapy were administered. The
median number of cycles per patient was 6 (range: 1–21 cycles); 12
patients received less than three cycles. In total, the median (range)
dose received per patient was 10304mgm
 2 (1856–37941) for
capecitabine and 681mgm
 2 (100–2507) for oxaliplatin. The
median (range) dose per treatment day was 1952mgm
 2 (930–
2128) for capecitabine and 128mgm
 2 (0–137) for oxaliplatin
(minimum of 78mgm
 2 if administered). Forty-one (82%)
patients were evaluable for tumour response. Among the nine
remaining patients, four patients (8%) received only one cycle of
chemotherapy and five patients (10%) two cycles. The cause of
death of these patients was liver cancer for seven, liver disease for
one, and toxicity for the other. The best tumour response was
partial response (PR) in 3 patients (7%), stable disease (SD) in 33
patients (81%), and disease progression in 5 patients (12%). Partial
response duration in the three patients was 1.1, 5.0, and 7.3 months
respectively, whereas duration of SD ranged from 2.2 to 20.5
months (median: 5.4 months). In the intention-to-treat group
(N¼50), the tumour control rate (PR and SD) was 72% (95%
confidence interval (CI) 57–83%). The tumour control rate was
77% (95% CI 61–88%) in the 43 patients with Child–Pugh A score
cirrhosis, including the three patients with PR. Among the 36
patients with at least two assessments of serum AFP, one complete
and four partial biological responses (defined by normalisation
and decrease level more than 50%, respectively) were observed. All
patients ended their XELOX treatment, the last one ending on
January 2006. The cutoff date for analysis was 1 July 2006. Median
patient follow-up using inverted Kaplan–Meier method was 26
months and ranged from 21 to 29 months in patients alive. Six
patients were alive at the cutoff date (all with disease progression).
Hepatocellular carcinoma was the cause of death in 37 (84%) out
of the 44 patients with progression (combined with cirrhosis
decompensation in four patients (9%)), cirrhosis decompensation
alone in four patients (9%), toxic death in two patients (5%), and
cardiac failure in one patient (2%). Median PFS and OS were 4.1
and 9.3 months, respectively. Estimated PFS was 38% (95% CI: 26–
52%) at 6 months and 14% (7–26%) at 12 months (Figure 1),
whereas OS was 56% (42–69%) at 6 months, 44% (31–58%) at 12
months, 26% (16–40%) at 18 months, and 15% (8–28%) at 24
months (Figure 1).
By univariate analysis in the overall population, OS was
significantly longer in patients with a Child–Pugh score of A
compared with score B patients (P¼0.0076), with a median OS of
10.4 vs 4.3 months (Figure 2), and there was a trend towards longer
OS (P¼0.056) in patients whose baseline PS was equal to zero
compared with other patients (PSX1). There were no significant
effects of age, CLIP score, and presence of clinical cirrhosis or
alcohol abuse on OS (data not shown). Using multivariate analysis
(Cox model), hazard ratio of death was 3.01 (95% CI: 1.25–7.26) in
patients with a Child–Pugh score of B compared with those
patients with a score of A (P¼0.014) (Table 2).
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Figure 1 Kaplan–Meier estimation of progression-free survival and
overall survival (N¼50).
Table 1 Patients’ baseline characteristics
Characteristics N¼50
Median age, years (range) 68 (24–82)
Gender
Male, n (%) 44 (88)
Female, n (%) 6 (12)
World Health Organization PS, n (%)
0 22 (44)
1 25 (50)
2 3 (6)
Cancer Liver Italian Program score, n (%)
0 1 (2)
1 18 (36)
2 19 (38)
3 12 (24)
Child–Pugh score, n (%)
A 43 (86)
B 7 (14)
Coexisting cirrhosis, n (%) 36 (72)
Aetiology of liver disease, n (%)
Alcohol
a 33 (66)
Hepatitis C 5 (10)
Hepatitis B 3 (6)
Hemochromatosis 4 (8)
Other
b 5 (10)
Median AFP
c,n gm l
 1 (range) 159 (11–487 221)
AFP¼alphafetoprotein.
aAlcohol abuse: alone in 28 patients (56%), with either
haemochromatosis (two patients, 4%) or hepatitis B virus (two patients, 4%) or
hepatitis C virus (one patient, 2%).
bNormal liver in two patients (4%); not otherwise
specified, unknown origin and degenerated adenomatosis in one patient (2%), each.
cIn the 40 patients with abnormal AFP level at baseline.
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Figure 2 Kaplan–Meier estimation of overall survival by Child–Pugh
score group (N¼50).
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All 50 patients but one who received only one cycle were evaluable
for toxicity. In total, 30 patients (61%) experienced at least one
grade 3 or 4 treatment-related toxicity (Table 3). The most
frequent grade 3–4 nonhaematologic toxicities were diarrhoea,
elevation of aminotransferases, and/or bilirubin, and fatigue.
Hand-foot syndrome was severe in only two patients. Grade 2
and 3 peripheral neuropathy was observed in 11 (22%) and 3 (6%)
patients, respectively. Only two patients had a severe neutropenia.
Six patients (12%) had grade 3–4 thrombocytopenia. The reason
for treatment withdrawal was disease progression in 30 patients
(60%), decompensated cirrhosis in 7 patients (14%), cardiac
failure in 1 patient (2%), treatment-related toxicity in 5 patients
(10%), patient’s refusal in 4 patients (8%), and other reason not
otherwise specified in 3 patients (6%). Two treatment-related
deaths were observed including one patient with myocardial
infarction concomitant with neutropenic infection and grade 3
diarrhoea after the first course of treatment, and one patient with
neutropenic pneumopathy after the third course of treatment.
DISCUSSION
There is no systemic chemotherapy that can be considered as a
standard for advanced HCC as no drug or combination has been
convincingly shown to improve survival over best supportive care
(Lai et al, 1988; Burroughs et al, 2004). In addition to intrinsic
resistance, underlying liver cirrhosis most often precludes the use
of several cytotoxic agents, namely cytotoxic agents metabolised
by the liver and excreted into the bile. The lack of renal toxicity
of oxaliplatin (Brienza et al, 1995), the low incidence of myelo-
suppression observed with capecitabine (Van Cutsem et al, 2001),
the synergistic anti-tumour activity of capecitabine and oxaliplatin
combination in advanced gastrointestinal cancers (Cassidy et al,
2004; Park et al, 2006b), and the absence of dose adjustment
required for both agents in case of hepatic dysfunction (Brienza
et al, 1995; Twelves et al, 1999) make the XELOX regimen
attractive in cirrhotic patients with HCC.
In the current study, XELOX regimen showed modest activity in
patients with advanced HCC using the RECIST criteria. Thus,
although it is difficult to compare the efficacy results from one to
another study because of heterogeneous tumour response criteria
and patient selection, our study did not confirm previous results of
clinical activity reported with capecitabine alone or FOLFOX
regimen (Frustaci et al, 2003; Patt et al, 2004). Higher tumour
response rates of 15–25% were previously obtained with
doxorubicin and cisplatin combinations with either capecitabine
or UFT. However, this did not seem to affect significantly PFS and
OS found to be less than 4 months and 8 months, respectively (Kim
et al, 2006; Park et al, 2006a). A recent randomised phase III study
comparing single agent doxorubicin vs PIAF regimen (cisplatin/
interferon a-2b/doxorubicin/fluorouracil) did not show any
significant difference in OS between the two arms despite
borderline statistical significance in favour of PIAF (6.8 and 8.7
months for doxorubicin and PIAF arms, respectively) (Yeo et al,
2005). Therefore, no drug or combination has been shown to be
better than single agent doxorubicin, which does not convincingly
i m p r o v es u r v i v a lo v e rs u p p o r t i v ec a r e .T h u s ,o n ec a na r g u et h a tt h e r e
is no standard chemotherapy and that supportive care has to be the
control group of any randomised trial (Burroughs et al, 2004).
With a disease control rate of 72%, a median survival of 9.3
months, and a one-year survival rate of 44%, the XELOX regimen
compares favourably with other systemic therapies for HCC. The 6
months PFS rate was 38%, suggesting that XELOX regimen was
capable of achieving durable stabilisation of advanced-stage HCC.
As assessment of response to treatment based on conventional
criteria that relies mainly on radiological evaluation may not be
reliable in advanced HCC (Yeo et al, 2005), PFS may be a more
appropriate and informative primary end point of further phase II
studies. This is all the more true and already the case for phase II
studies assessing the efficacy of new targeted therapies that may be
cytostatic instead of cytotoxic (Philip et al, 2005; Abou-Alfa et al,
2006). As an example, recent phase III results of sorafenib, a
multikinase inhibitor targeting Raf kinase, vascular endothelial
growth factor receptor, and platelet-derived growth factor
receptor, have demonstrated a statistically significant improve-
ment in OS and time to progression (TTP) in a comparable patient
population with advanced HCC, despite a low response rate
according to the RECIST criteria observed in a previous phase II
study (Abou-Alfa et al, 2006; Llovet et al, 2007): median OS was
10.7 months in the sorafenib group as compared to 7.9 months in
the placebo group (HR¼0.69, P¼0.0006), and median TTP was
5.5 vs 2.8 months, respectively (HR¼0.58, P¼0.000007).
The toxicity profile was acceptable in our trial including patients
with HCC and underlying cirrhosis. Haematologic toxicity was
mild compared with that observed with anthracyclin-based
polychemotherapy regimens. Grade 3–4 thrombocytopenia and
neutropenia was observed in 12 and 4% of the population,
respectively. Although no direct comparison with our previous
phase II with gemcitabine/oxaliplatin regimen, the use of
capecitabine instead of gemcitabine in combination to oxaliplatin
resulted in lower haematological toxicity (Louafi et al, 2007). Of
note, the threshold value of platelet count as an inclusion criteria
was decrease to 75gl
 1 because of frequent baseline portal
Table 3 Treatment-related toxicities in 49 patients
Grade 1–2 Grade 3–4
No. of patients
(%)
No. of patients
(%)
Thrombocytopenia 17 (35%) 6 (12%)
Transaminases or bilirubin 31 (63%) 8 (16%)
Diarrhoea 18 (37%) 8 (16%)
Anaemia 31 (63%) 6 (12%)
Neurotoxicity 37 (76%) 3 (6%)
a
Nausea/vomiting 26 (53%) 2 (4%)
Neutropenia 14 (29%) 2 (4%)
Hand foot syndrome 17 (35%) 2 (4%)
Mucocitis 7 (14%) 1 (2%)
Other 29 (59%) 6 (12%)
b
Toxic deaths
Myocardial infarction in
neutropenia
1 (6%)
Aplastic pneumopathy 1 (6%)
aAt cycles 8, 9, and 11, respectively.
bFour fatigue, one fatigue and lombalgia, one
fatigue and anorexia, one fatigue and hypokalemia, one liver pain, one hypercrea-
tininemia, one leucopenia, one constipation, and one diabetes decompensation.
Table 2 Univariate and multivariate analyses of overall survival (N¼50)
Univariate analysis Multivariate analysis
n
12-month OS
(95% CI) P-value
a HR (95% CI) P-value
b
Child–Pugh score
A 43 49% (35–63%) 0.0076 1 0.0140
B 7 14% (3–51%) 3.01 (1.25–7.26)
PS (WHO)
0 22 59% (39–77%) 0.056 1 0.070
1–2 28 32% (18–51%) 1.76 (0.95–3.26)
OS¼overall survival; CI, confidence interval; HR¼hazard ratio; PS¼performance
status.
aLog-rank test.
bCox model. Bold values signifies o0.05.
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shypertension associated thrombocytopenia under 100gl
 1. De-
spite a potential risk of bleeding from oesophageal varices, yet no
bleeding episodes occurred, possibly owing to close monitoring
and dose adjustment. We also observed liver dysfunction as
measured by an increase in hepatic transaminase and hyperbili-
rubinemia. However, severe liver test abnormalities may be due, in
part, to coexisting chronic liver disease since oxaliplatin and
capecitabine were not found to be hepatotoxic in patients with
CRC except benign and unexplained isolated hyperbilirubinemia
occasionally observed under capecitabine treatment (Van Cutsem
et al, 2001). Otherwise, no HBV reactivation was observed despite
no systematic lamivudin prophylaxis in HBsAg-positive patients.
We also conducted exploratory analysis of prognostic factors.
Only the Child–Pugh score was consistently associated withOS.
These findings are consistent with those of previous reports in
which low bilirubin, high albumin level, and absence of ascites
were associated with improved survival of HCC patients after
chemotherapy, as those factors are included in the Child–Pugh
score (Okada 1998; Leung et al, 2002; Yeo et al, 2005).
Interestingly, albumin level has also been shown to be a prognostic
factor of treatment outcome in HCC patients receiving doxo-
rubicin-based regimen (Yeo et al, 2005). Stratification of patients
according to specific prognostic scores used in HCC and cirrhosis
should be included in future trials designed to better identify
patients who may benefit from systemic chemotherapy.
CONCLUSION
Despite a disease control rate of 72% and a favourable toxicity
profile, XELOX regimen had a modest anti-tumour activity for
patients with advanced HCC and cirrhosis. Future phase II and III
trials should assess the efficacy of new promising treatment
approaches such as molecularly targeted therapies alone or in
combination with cytotoxic agents using appropriate primary end
point, and also define predictive biomarkers according to the
drug’s mechanism of action and the biologic behaviour of the
tumour.
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